The Dales Report – BayMedica Unveils Industry Leading Portfolio

Jul 14, 2022

Jerry P. Griffin, VP of Sales and Marketing at BayMedica, InMed’s subsidiary, is interviewed by Shadd Dales of the The Dales Report to talk about the recent B2B sales launch of rare cannabinoid #tetrahydrocannabivarin #d9 #THCV into the health and wellness sector.

Excerpt:

While BayMedica is conducting business activities with many different types of health and wellness companies, Jerry gives an interesting account about the interest coming from U.S. multi-state operators (MSOs) in the cannabis industry. To help optimize the effectiveness of their products—to counterbalance the effects of THC, for example—MSOs are increasingly infusing cannabinoids into edibles formulations. Edibles currently account for about 9% of the U.S. cannabis market, and that metric has been steadily rising over time.

Read full article and watch video via The Dales Report.

Interested in learning more about our rare cannabinoids?